Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment

Ki vehet részt

• Patients aged 18 and older with moderate to severe orbitopathy
• Patients followed in endocrinology with the goal of achieving euthyroidism
• Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS)
• Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy
• Patients with a CAS ≥ 3 or CAS <3 with moderate to severe orbitopathy (according to EUGOGO)
• Patients treated with immunotherapy, biotherapy, or radiotherapy as second-line treatment
• Patients who are not opposed to the reuse of their health data

Ki nem vehet részt

• Patients who have undergone bone or fat decompression surgery
• Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy
• Patients with severe corneal involvement (Grade B or C; NO SPECS classification)
• Patients with optic neuropathy (Grade B and C; NO SPECS classification)
• Patients who have opposed the reuse of their health data